JMP Securities Reiterates Market Outperform on Terns Pharma, Maintains $15 Price Target
Portfolio Pulse from Benzinga Newsdesk
JMP Securities analyst Silvan Tuerkcan has reiterated a Market Outperform rating for Terns Pharma (NASDAQ:TERN) and maintained a price target of $15.
September 03, 2024 | 12:31 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
JMP Securities has reiterated a Market Outperform rating for Terns Pharma, maintaining a $15 price target, indicating confidence in the company's potential.
The reiteration of a Market Outperform rating and maintenance of a $15 price target by JMP Securities suggests a positive outlook for Terns Pharma. This could lead to increased investor confidence and potential upward movement in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100